Imagine being able to take a real-time chemical snapshot of exactly what is happening inside the human body. That is the power of metabolomics, the comprehensive study of small molecules, or metabolites. Metabolomics can detect biochemical shifts in our well-being, allowing doctors to identify and correct imbalances or assess disease progression or treatment effectiveness before symptoms appear.
This shift toward proactive health optimization is a massive economic driver. The U.S. metabolomics market is rapidly approaching a $1 billion annual valuation, serving as the foundation for the broader personalized healthcare industry, which is projected to surpass $1.3 trillion globally over the next decade.
To make personalized health a reality, the U.S. biotechnology industry requires reliable and reproducible data. This is where NIST comes in by creating Reference Materials (RMs) that are homogenous across a diverse chemical profile and qualitatively characterized with highly confident annotations that offer a fundamental benchmark for measurement performance, data comparability, analyst training, and annotation and identification checks. By providing metabolomics reference standards, NIST helps healthcare and wellness companies have confidence in their results, lower research and development costs, and bring reliable products to market faster.
To support this booming industry, NIST has released two new foundational reference materials:
As the US National Metrology Institute (NMI), NIST materials like RM 8232 and RM 8462 provide the scientific and industrial communities with highly stable, homogeneous samples that give labs the tools they need to validate instrument performance, develop new methods, and ensure their measurements are consistent with other laboratories. These new RMs combined with the recently released Frozen Human Plasma Suite (RM 8231) and Human Fecal Material (RM 8048), now provide a set of matrices covering the major biological samples used in clinical testing. By supplying the extreme rigor necessary for untargeted metabolomics, NIST ensures that the U.S. biotechnology industry has the measurement foundation required to invent the personalized healthcare technologies of tomorrow.